The price per dose of the Russian coronavirus vaccine Sputnik V will be much lower than that of the vaccines of US drug giants Pfizer and Moderna, said the Russian vaccine's official Twitter account on Sunday.
"Translating pharma lingo: the announced price of Pfizer of USD 19.50 and Moderna of USD 25-USD 37 per dose actually means their price of USD 39 and USD 50-USD 74 per person. Two doses are required per person for the Pfizer, Sputnik V and Moderna vaccines. The price of Sputnik V will be much lower," the official account said.
Russia became the first country to register the world's first COVID-19 vaccine on August 11. Sputnik V was developed by the Gamaleya National Research Centre for Epidemiology and Microbiology of the Russian Healthcare Ministry.
On November 11, Russia had said that its vaccine Sputnik V is 92 per cent effective at protecting people from COVID-19 according to the first interim analysis.
On November 17, Moderna, in its official statement, had announced that the independent, U.S. NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273 has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%.
Similarly, on November 18, Pfizer had said that final results from the late-stage trial of its coronavirus vaccine was found to be 95 per cent effective and had no serious side effects on older people.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU